September 20, 2025Journal of Clinical MedicineOpen Access

Clinical Characteristics and Management of Statin-Associated Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy

View Full Paper

Ask AI

Bookmark

Delayed treatment initiation after symptom onset correlates with unfavorable outcomes in patients with anti-HMGCR-positive IMNM.
Initial CK levels in patients ranged from 1438 to over 13,000 IU/L, indicating severe muscle damage.
A retrospective review of 10 patients diagnosed with anti-HMGCR-positive IMNM highlighted significant diagnostic delays.
Treatment strategies included corticosteroids and multiple immunosuppressive agents to manage symptoms and improve recovery.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis reveals challenges in diagnosing and treating anti-HMGCR-positive myopathy in patients on statins.

Yoon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark